SCHEMBL1410185

SCHEMBL1410185

NCCCCOC(=O)c1ccccc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.81
LMNA P02545 2/20 0.59
MAPK1 P28482 1/20 0.52
HIF1A Q16665 1/20 0.52
SLC6A2 P23975 1/20 0.52
SLC6A3 Q01959 1/20 0.52
KMT2A Q03164 1/20 0.52
ALDH1A1 P00352 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
MAPT P10636 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
KDM4E B2RXH2 1/20 0.49
GAA P10253 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
TSHR P16473 1/20 0.49
CYP2C19 P33261 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2778301 0.98 TDP1 (0.79) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL28093034 0.98 TDP1 (0.79) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL2777961 0.98 TDP1 (0.79) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL2777301 0.98 TDP1 (0.79) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL7292310 0.94 TDP1 (0.78) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL223441 0.90 TDP1 (1.00) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL14613137 0.90 TDP1 (0.66) TDP1LMNAALDH1A1NPC1RAB9A
SCHEMBL2069111 0.88 TDP1 (0.96) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL225815 0.88 TDP1 (0.96) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL17466182 0.88 TDP1 (0.96) TDP1LMNAMAPK1HIF1ASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107108638-A Piperidyl PyrazolopyrimidinonecGMP and application thereof 拜耳制药股份公司 2017-08-29 CN claimed
CN-105683194-A (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones as inhibitors of fibrinolysis 拜耳制药股份公司 2016-06-15 CN claimed
US-11708320-B2 Environmentally-friendly hydroazidation of olefins GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2023-07-25 US disclosed
US-20210284601-A1 ENVIRONMENTALLY-FRIENDLY HYDROAZIDATION OF OLEFINS GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. 2021-09-16 US disclosed
CN-105683194-B The inhibitor of (azepine) pyrido PyrazolopyrimidinonecGMP and indazole hepyramine as fibrinolysis 拜耳制药股份公司 2018-09-14 CN disclosed
CN-107108638-A Piperidyl PyrazolopyrimidinonecGMP and application thereof 拜耳制药股份公司 2017-08-29 CN disclosed
CN-105683194-A (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones as inhibitors of fibrinolysis 拜耳制药股份公司 2016-06-15 CN disclosed
CN-103127402-A Application of swallow cimitin in preparation of whitening and freckle removing product YANG YANJIAO 2013-06-05 CN disclosed
CN-102712933-A regulated expression system PROYECTO BIOMEDICINA CIMA SL 2012-10-03 CN disclosed
CN-102112616-A System for packaging high-capacity adenoviruses PROYECTO BIOMEDICINA CIMA SL 2011-06-29 CN disclosed
CN-102099481-A Self-inactivating helper adenoviruses for production of high-capacity recombinant adenoviruses PROYECTO BIOMEDICINA CIMA SL 2011-06-15 CN disclosed
US-20050256051-A1 Nuclear receptor-mediated introduction of a PNA into cell nuclei THE POPULATION COUNCIL, INC. (US) 2005-11-17 US disclosed
EP-1392366-A4 NUCLEAR RECEPTOR-MEDIATED INTRODUCTION OF A PNA INTO CELL NUCLEI POPULATION COUNCIL INC (US) 2005-01-19 EP disclosed
EP-1392366-A1 NUCLEAR RECEPTOR-MEDIATED INTRODUCTION OF A PNA INTO CELL NUCLEI THE POPULATION COUNCIL, INC. (US) 2004-03-03 EP disclosed
US-20030096739-A1 Nuclear receptor-mediated introduction of a PNA into cell nuclei POPULATION COUNCIL, INC., THE 2003-05-22 US disclosed
WO-2002083186-A1 NUCLEAR RECEPTOR-MEDIATED INTRODUCTION OF A PNA INTO CELL NUCLEI THE POPULATION COUNCIL, INC. (US) 2002-10-24 WO disclosed
EP-0822991-A4 METHODS, POLYPEPTIDES, NUCLEOTIDE SEQUENCE OF XOR-6, A VITAMIN D-LIKE RECEPTOR FROM XENOPUS SALK INST FOR BIOLOGICAL STUDI (US) 2000-11-02 EP disclosed
WO-1999032649-A1 METHODS AND PRECURSORS FOR THE PRODUCTION OF CHIRAL 1,3-AMINOALCOHOLS BIOCATALYTICS, INC. (US) 1999-07-01 WO disclosed
EP-0822991-A1 METHODS, POLYPEPTIDES, NUCLEOTIDE SEQUENCE OF XOR-6, A VITAMIN D-LIKE RECEPTOR FROM XENOPUS THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1998-02-11 EP disclosed
WO-1996022390-A1 METHODS, POLYPEPTIDES, NUCLEOTIDE SEQUENCE OF XOR-6, A VITAMIN D-LIKE RECEPTOR FROM XENOPUS THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1996-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708320-B2 Environmentally-friendly hydroazidation of olefins HAO2, AHR, HMOX1 TDP1 2142/4885LMNA 4815/4885MAPK1 2501/4885
US-20210284601-A1 ENVIRONMENTALLY-FRIENDLY HYDROAZIDATION OF OLEFINS HAO2, AHR, HMOX1 TDP1 2142/4885LMNA 4815/4885MAPK1 2501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.